Results 221 to 230 of about 5,456,142 (288)

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source

Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases. [PDF]

Research (Wash D C)
Shen D, Chen R, Ye S.
europepmc   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care. [PDF]

Clin Exp Gastroenterol
Vo TD.
europepmc   +1 more source

Toward a Synthetic Data Revolution: Diffusion Model‐Enhanced Hepatocellular Carcinoma Prediction in Steatotic Liver Disease

Hepatology Research, EarlyView.
ABSTRACT Aim Steatotic liver disease (SLD) encompasses a heterogeneous spectrum with varying risks of hepatocellular carcinoma (HCC). Limited sample sizes limit the development of predictive models, particularly for rare outcomes. This study evaluated whether generative artificial intelligence (AI)‐based synthetic data augmentation can enhance HCC risk
Masaya Sato, Takuma Nakatsuka, Yuki Matsushita, Takuma Kaneko, Keisuke Mabuchi, Tomoharu Yamada, Kazuya Okushin, Tatsuya Minami, Yotaro Kudo, Satoshi Kodera, Kazuhiko Koike, Mitsuhiro Fujishiro, Ryosuke Tateishi   +12 more
wiley   +1 more source

Editorial: Liver and Non-Liver Outcomes Between Different Subtypes of Steatotic Liver Disease. [PDF]

Aliment Pharmacol Ther
Huang JF, Yu ML, Chuang WL.
europepmc   +1 more source

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

Hepatology Research, EarlyView.
We carried out proteomic analysis of serum extracellular vesicles to identify biomarkers predictive of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B receiving nucleos(t)ide analog therapy. Candidate proteins identified through proteomic analysis were subsequently quantified in serum by ELISA.
Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, Satoshi Shigeno, Yuta Myojin, Kazuki Maesaka, Kumiko Shirai, Yuki Makino, Yuki Tahata, Yoshinobu Saito, Takahiro Kodama, Ryotaro Sakamori, Jun Adachi, Tomomi Yamada, Tetsuo Takehara   +21 more
wiley   +1 more source

Conducting the Orchestra: Nonparenchymal Cells Direct Hepatocyte Functions in Steatotic Liver Disease. [PDF]

Cell Mol Gastroenterol Hepatol
Jaeger JW, Schwabe RF.
europepmc   +1 more source

Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis

Hepatology Research, EarlyView.
Pemafibrate improves liver function markers related to bile flow in primary biliary cholangitis (PBC), but whether this effect is disease‐specific remains unclear. In this study, pemafibrate reduced these markers in patients with and without PBC, suggesting broader effects on bile flow beyond PBC.
Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, Ayumi Saito, Hideki Suganami, Atsushi Tanaka   +5 more
wiley   +1 more source

Helicobacter pylori Infection and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis. [PDF]

Cancer Epidemiol Biomarkers Prev
Zhao L, Chen Y, Zhang X, Mezzacappa C, Ma X, Banini B, Lee JE, Liu C, Zhang X, Hsing AW, Nguyen MH, Hyun CS, Camargo MC, McGlynn KA, Hou L, Taddei TH, Zhang X.   +16 more
europepmc   +1 more source